Report
Novo signs licensing deal for Hengrui Pharma weight-loss treatment
The Wall Street Journal reports that Hengrui Pharma is developing the treatment and that the deal could be worth up to $2.6 billion.
TLDR
The Wall Street Journal reports that Novo signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma. The deal could be worth up to $2.6 billion.
Combined views
165.8K
5 Sources, first seen ago
